News

Final guidance issued on Herceptin after appeal rejected

BMJ 2006; 333 doi: 10.1136/bmj.333.7565.409 (Published 24 August 2006)
Cite this as: BMJ 2006;333:409.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Caroline White
  1. London

    The National Institute for Health and Clinical Excellence (NICE) has issued its final guidance to English and Welsh health service trusts for the use of trastuzumab (Herceptin) for the treatment of early stage breast cancer in women with HER2 positive disease and free of heart disease.

    The final guidance is based on an initial draft published earlier this year (BMJ 2006; 332: 1409). It recommends that:

    • Herceptin be provided at three weekly intervals for a year or until disease recurrence—whichever is sooner—after surgery, chemotherapy, and radiotherapy, if …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular